Zacks: Brokerages Expect Melinta Therapeutics Inc (NASDAQ:MLNT) Will Post Quarterly Sales of $15.51 Million

Wall Street brokerages forecast that Melinta Therapeutics Inc (NASDAQ:MLNT) will report $15.51 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Melinta Therapeutics’ earnings. The highest sales estimate is $15.80 million and the lowest is $15.21 million. Melinta Therapeutics reported sales of $34.08 million in the same quarter last year, which indicates a negative year over year growth rate of 54.5%. The business is scheduled to report its next quarterly earnings report on Wednesday, November 6th.

On average, analysts expect that Melinta Therapeutics will report full-year sales of $65.84 million for the current year, with estimates ranging from $61.97 million to $73.00 million. For the next financial year, analysts anticipate that the firm will report sales of $78.94 million, with estimates ranging from $65.99 million to $91.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Melinta Therapeutics.

Melinta Therapeutics (NASDAQ:MLNT) last announced its quarterly earnings data on Friday, August 9th. The biotechnology company reported ($3.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.57) by ($0.50). Melinta Therapeutics had a negative return on equity of 60.39% and a negative net margin of 135.23%. The firm had revenue of $15.96 million during the quarter, compared to analysts’ expectations of $14.00 million.



Several research analysts have recently issued reports on the company. Gabelli restated a “sell” rating on shares of Melinta Therapeutics in a research note on Thursday, June 20th. HC Wainwright cut Melinta Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 12th. ValuEngine upgraded Melinta Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, September 4th. Cantor Fitzgerald set a $15.00 price objective on Melinta Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 19th. Finally, Zacks Investment Research cut Melinta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 17th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. Melinta Therapeutics presently has an average rating of “Hold” and a consensus target price of $27.21.

Shares of NASDAQ:MLNT traded down $0.28 during trading on Friday, hitting $3.54. The stock had a trading volume of 850,400 shares, compared to its average volume of 1,197,444. Melinta Therapeutics has a 12-month low of $1.62 and a 12-month high of $23.00. The stock has a market capitalization of $49.34 million, a price-to-earnings ratio of -0.20 and a beta of 4.40. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 1.11. The stock has a 50-day simple moving average of $2.73 and a two-hundred day simple moving average of $3.78.

A number of hedge funds have recently made changes to their positions in MLNT. Bank of Montreal Can raised its position in Melinta Therapeutics by 253.2% during the second quarter. Bank of Montreal Can now owns 5,503 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 3,945 shares in the last quarter. Morgan Stanley raised its position in Melinta Therapeutics by 82.9% during the second quarter. Morgan Stanley now owns 10,822 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 4,906 shares in the last quarter. Condor Capital Management purchased a new position in Melinta Therapeutics during the second quarter valued at approximately $93,000. Parametric Portfolio Associates LLC purchased a new position in Melinta Therapeutics during the second quarter valued at approximately $142,000. Finally, Paloma Partners Management Co purchased a new position in Melinta Therapeutics during the second quarter valued at approximately $205,000. Institutional investors own 19.47% of the company’s stock.

About Melinta Therapeutics

Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens.

Recommended Story: Buy Rating

Get a free copy of the Zacks research report on Melinta Therapeutics (MLNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Melinta Therapeutics (NASDAQ:MLNT)

Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.